To sign up for our newsletter or print publications, please enter your contact information below.
Engineering CAR T Cells to Eliminate Problems
<![CDATA]>(MedPage Today) — A novel anti-CD19 CAR T-cell therapy attained a high response rate with minimal neurotoxicity in patients with advanced B-cell lymphoma, according to a preliminary clinical trial. The…
<![CDATA]>(MedPage Today) — The FDA approved olaparib (Lynparza) on Monday as a maintenance therapy for metastatic pancreatic cancer patients with germline BRCA mutations and platinum-sensitive disease, drugmakers AstraZeneca and Merck… Source link [ Read More ]